Off-the-shelf Lead mAbs, Ready to Out-Licensing

To help pharmaceutical companies accelerate the preclinical development of antibody drugs, DIMA BIOTECH (hereinafter referred to as “DIMA”) has launched the “All Druggable Targets” lead antibody molecule development program, leveraging its proprietary, innovative single B cell development platform. DIMA will generate lead antibody molecules and corresponding B cell seed libraries targeting all druggable targets. Clients can directly import lead antibody molecules from DIMA or rapidly screen for additional lead antibodies from the B cell seed library. Compared to traditional hybridoma technology, DIMA can save clients up to nearly a year in development time.

To date, DIMA has screened over 5,000 lead antibody sequences, covering over 500 druggable targets. All of these have been sequenced and are available for global licensing. For some popular target sequences, DIMA has also conducted human-monkey cross-talk and in vitro functional validation. Clients can immediately import sequences and data packages for functional validation, enabling them to be one step ahead and seize market opportunities.